SGCB and chronic obstructive pulmonary disease: Seven studies (Alkhayat and Eid, 2016; Li et al., 2021; Alp et al., 2006; Vitulo et al., 2017; Shrestha et al., 2017; Pichl et al., 2019; Maron et al., 2022) evaluated whether medications targeting the NO-sGC-cGMP pathway can improve exercise capacity (assessed as a 6-min walk test (6MWT)) in COPD patients with PH.